Physician profile
Katherine Gresham
NPI 1225652720
$13,689.59
in general payments reported to CMS, 2019-2025
52 companies · $2,551 in 2025
The $2,551 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,547 · 2022: $2,527 · 2023: $3,026 · 2024: $3,039 · 2025: $2,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,521 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,520.56 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,662.92 | 2021-2025 | |
| Novo Nordisk INC | $950.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $932.70 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $893.25 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $728.22 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $718.04 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $700.29 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $626.26 | 2021-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $483.46 | 2022-2025 | Sunosi, Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $358.55 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $343.31 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $258.32 | 2021-2022 | |
| Esperion Therapeutics, INC. | $257.58 | 2021-2025 | Nexletol |
| Lundbeck LLC | $252.56 | 2022-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $246.67 | 2021-2024 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Gresham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.